Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the Caribbean tunicate, Ecteinascidia turbinate ("sea squirt"). The compound is now produced synthetically. Trabectedin binds to the minor groove of DNA, interfering with cell division and genetic transcription processes and DNA repair machinery. Trabectedin is currently in Phase 3 development in ovarian cancer and to expand its uses in sarcoma.
According to the licensing agreement, PharmaMar SAU has rights to market the compound in Europe and Japan, while Centocor Ortho Biotech Products, L.P. has marketing rights for the product in the rest of the world.
About Centocor Ortho Biotech Products, L.P.
Centocor Ortho Biotech redefines the standard of care in immunology, nephrology, and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Products, L.P. were consolidated in late 2008, and was renamed Centocor Ortho Biotech. Built upon a pioneering history, Centocor Ortho Biotech harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care.
Note: This release corresponds to ASCO abstracts 5526, 5550, 5551, 8591 and 9625
|SOURCE Centocor Ortho Biotech Products, L.P.|
Copyright©2009 PR Newswire.
All rights reserved